Published in Circ Res on May 03, 2007
Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res (2009) 1.14
A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development (2013) 1.01
Silky, sticky chimeras-designer VEGFs display their wares. Circ Res (2007) 0.77
Reciprocal modulation of Aβ42 aggregation by copper and homocysteine. Front Aging Neurosci (2014) 0.75
Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Sci Rep (2017) 0.75
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol (2003) 12.96
Copy number variation and selection during reprogramming to pluripotency. Nature (2011) 8.24
Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol (2007) 7.75
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2003) 7.42
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Lymphangiogenesis in development and human disease. Nature (2005) 5.93
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest (2005) 4.09
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer (2002) 3.90
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med (2004) 3.32
PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev (2005) 3.29
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
The biology of vascular endothelial growth factors. Cardiovasc Res (2005) 3.22
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol (2002) 2.99
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood (2004) 2.95
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol (2008) 2.85
Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (2002) 2.68
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood (2002) 2.52
Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol (2008) 2.49
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med (2011) 2.38
Signaling and functions of angiopoietin-1 in vascular protection. Circ Res (2006) 2.34
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood (2009) 2.30
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med (2007) 2.29
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res (2003) 2.25
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol (2009) 2.17
Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res (2008) 2.15
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol (2004) 2.13
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol (2011) 2.09
Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood (2010) 2.04
Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev (2005) 2.01
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest (2013) 1.92
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol (2005) 1.91
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
Biological basis of therapeutic lymphangiogenesis. Circulation (2011) 1.85
Vascular growth factors and lymphangiogenesis. Physiol Rev (2002) 1.85
Gene transfer as a tool to induce therapeutic vascular growth. Nat Med (2003) 1.85
Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell (2008) 1.82
Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci (2002) 1.82
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A (2004) 1.82
Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood (2011) 1.82
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer (2002) 1.80
Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J (2006) 1.79
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A (2003) 1.79
Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood (2005) 1.75
Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res (2004) 1.74
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res (2007) 1.73
CKIα ablation highlights a critical role for p53 in invasiveness control. Nature (2011) 1.72
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol (2010) 1.72
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood (2005) 1.71
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med (2010) 1.69
Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO J (2006) 1.69
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation (2003) 1.67
Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J (2002) 1.67
Specific induction of tie1 promoter by disturbed flow in atherosclerosis-prone vascular niches and flow-obstructing pathologies. Circ Res (2003) 1.64
An important role of lymphatic vessel activation in limiting acute inflammation. Blood (2011) 1.62
Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J (2002) 1.62
Gene therapy for malignant glioma: current clinical status. Mol Ther (2005) 1.61
Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci U S A (2010) 1.60